Nektar Therapeutics (NASDAQ:NKTR) announced its earnings results on Tuesday. The biopharmaceutical company reported $0.37 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.21 by $0.16, Briefing.com reports. The firm had revenue of $152.90 million for the quarter, compared to the consensus estimate of $126.50 million. Nektar Therapeutics had a negative return on equity of 1,223.34% and a negative net margin of 157.14%. The business’s quarterly revenue was up 321.2% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.32) EPS.

Shares of Nektar Therapeutics (NASDAQ:NKTR) traded up $2.56 on Tuesday, reaching $26.84. The company’s stock had a trading volume of 2,766,610 shares, compared to its average volume of 1,091,820. The company has a debt-to-equity ratio of 72.60, a quick ratio of 3.82 and a current ratio of 3.97.

In other news, SVP Stephen K. Doberstein sold 43,677 shares of the business’s stock in a transaction that occurred on Thursday, October 5th. The stock was sold at an average price of $24.97, for a total value of $1,090,614.69. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, SVP Stephen K. Doberstein sold 1,701 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $19.32, for a total value of $32,863.32. Following the completion of the transaction, the senior vice president now owns 31,102 shares in the company, valued at approximately $600,890.64. The disclosure for this sale can be found here. Insiders have sold a total of 623,317 shares of company stock valued at $14,352,710 over the last three months. Corporate insiders own 5.44% of the company’s stock.

WARNING: “Nektar Therapeutics (NKTR) Announces Quarterly Earnings Results” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be accessed at https://www.watchlistnews.com/nektar-therapeutics-nktr-announces-quarterly-earnings-results/1686338.html.

NKTR has been the topic of several recent research reports. Jefferies Group LLC reaffirmed a “buy” rating and set a $23.00 target price on shares of Nektar Therapeutics in a report on Friday, August 18th. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a report on Tuesday, August 1st. Roth Capital set a $33.00 price objective on Nektar Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 9th. HC Wainwright started coverage on Nektar Therapeutics in a research note on Monday, August 7th. They issued a “buy” rating and a $31.00 price objective on the stock. Finally, Mizuho started coverage on Nektar Therapeutics in a research note on Tuesday, September 26th. They issued a “buy” rating and a $30.00 price objective on the stock. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and ten have issued a buy rating to the company’s stock. Nektar Therapeutics currently has a consensus rating of “Buy” and an average price target of $26.80.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Earnings History for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.